Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Anktiva

(ank-TEE-vuh)
A drug used with bacillus Calmette-Guérin (BCG) to treat adults with bladder cancer that has not invaded the muscle layers of the bladder and with carcinoma in situ. Patients may or may not have a papillary tumor (a tumor that looks like long, thin “finger-like” growths). Anktiva is used in patients whose cancer has not gotten better after treatment with BCG. It is given with BCG as a solution through a catheter (thin tube) that is placed into the bladder. It is also being studied in the treatment of other types of cancer. Anktiva binds to receptors for the protein interleukin-15 (IL-15), which is found on certain types of immune cells. This may help the immune cells kill cancer cells better than BCG alone. Anktiva is a type of IL-15 receptor agonist and a type of immunotherapy. Also called nogapendekin alfa inbakicept.
Search NCI's Dictionary of Cancer Terms